What is the current market size?

The Age-related Macular Degeneration market size reached USD 1.2 billion in 2023, driven by rising geriatric populations and advanced treatment adoption.

What is the expected growth rate?

The AMD market is projected to grow at a 5.5% CAGR from 2026 to 2033, with a future outlook exceeding USD 2.1 billion by 2033.

What are the key growth drivers?

Key drivers include aging demographics, increased awareness of early detection, and innovation in biologics and gene therapy for AMD.

What challenges does the market face?

Challenges include high treatment costs, limited access in emerging economies, and side effects of current anti-VEGF therapies.

Which regions lead the AMD market?

North America dominates due to robust healthcare infrastructure, while Europe holds significant market share from Roche and Novartis operations.

Who are the top companies?

Leading players include Roche, Novartis, Allergan, and Bayer, focusing on sustained drug delivery systems and novel pipeline candidates.

What are future opportunities?

Emerging opportunities lie in AI-driven diagnostics, regenerative therapies, and partnerships targeting cost-effective treatment solutions.

How is technology impacting the market?

Advancements in OCT imaging, AI algorithms for early detection, and smart injection devices are transforming patient management in AMD care.

What is the regulatory landscape?

Regulators like FDA and EMA prioritize accelerated approvals for orphan drugs, while value-based pricing models reshape reimbursement frameworks.

How will emerging markets contribute?

Asia-Pacific markets, particularly India and China, will drive growth via expanding healthcare access and rising prevalence of AMD.

Age-related Macular Degeneration Growth, Trends & Forecast Outlook 2033

Age-related Macular Degeneration by Type (Wet AMD, Dry AMD), by Application (Drugstore, Hospital, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $7949.4 million

CAGR: 5.6%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $7949.4 million

CAGR: 5.6%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Age-related Macular Degeneration Market Overview

Age-related Macular Degeneration (AMD) is a progressive eye condition impacting central vision, driven by macula deterioration, and is a leading cause of irreversible vision loss in adults over 50. The Age-related Macular Degeneration market size is projected to reach USD 6.2 billion in 2025, reflecting a CAGR of 7.3% (2026–2033), fueled by aging populations and advanced therapeutic innovations. This market forecast underscores the industry expansion potential amid rising prevalence, with North America dominating due to high healthcare spending and Asia-Pacific emerging as the fastest-growing region due to demographic shifts and improving diagnostic access.

Loading chart…

Key forces shaping the Age-related Macular Degeneration market include technological shifts toward personalized gene therapies, regulatory support for accelerated drug approvals, and consumer behavior trends favoring early intervention. Anti-VEGF therapies remain dominant, but gene therapy adoption is surging, driven by FDA approvals and clinical trial breakthroughs. North America leads with USD 3.2 billion in revenue (2025), while Asia-Pacific’s 9.1% CAGR (2026–2033) highlights untapped opportunities in markets like India and China. Strategic collaborations and pipeline diversification are critical for stakeholders to capitalize on this growth outlook.

Report Overview

Report Attribute	Details
Market size value in 2025	7.95 billion
Revenue forecast in 2033	12.29 billion
Growth rate	CAGR of 5.6% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bayer HealthCare; F. Hoffmann-La Roche; Novartis; Regeneron Pharmaceuticals; Alcon; Allergan; Avalanche; Bausch+Lomb; Gilead Sciences; Iconic Therapeutics; Neurotech Pharmaceuticals; Ohr Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Aging global population: The rising prevalence of Age-related Macular Degeneration (AMD) among geriatric populations, particularly in developed regions like North America and Europe, is a key driver. With life expectancy increasing, the Age-related Macular Degeneration market size is projected to expand significantly, fueled by higher demand for diagnostic tools and therapeutic interventions.

Advancements in gene therapy and anti-VEGF treatments: Breakthroughs in regenerative medicine, including gene-editing technologies and novel anti-VEGF (vascular endothelial growth factor) therapies, are accelerating treatment efficacy. These innovations are expected to drive the growth forecast for the AMD market, offering long-term solutions for both dry and wet AMD variants.

Restraints2 items

High treatment costs and limited insurance coverage: Advanced therapies such as intravitreal injections and gene therapy remain prohibitively expensive, restricting patient access. In many emerging markets, inadequate reimbursement frameworks further hinder market penetration.

Diagnostic delays due to low awareness: Late-stage diagnosis of AMD remains common, particularly in rural and low-income regions. Limited access to ophthalmologists and underutilization of AI-driven diagnostic tools slow early intervention, reducing overall market demand for curative therapies.

Opportunities2 items

Expansion into emerging markets: Growing healthcare infrastructure and rising disposable incomes in Asia-Pacific and Latin America present untapped potential. Strategic partnerships with local distributors can enhance market reach and accelerate the Age-related Macular Degeneration market expansion.

Personalized medicine and biomarker research: The development of biomarker-based diagnostics and tailored treatment protocols offers a competitive edge. Companies leveraging AI and big data analytics can capture market share by improving patient outcomes and reducing trial-and-error prescribing.

Challenges2 items

Regulatory complexities and clinical trial hurdles: Stringent FDA and EMA guidelines for ocular drug approvals prolong time-to-market. Additionally, recruiting patients for phase III trials is challenging due to AMD’s slow progression and heterogeneous patient profiles.

Competition from biosimilars and generics: The entry of biosimilar anti-VEGF drugs is intensifying price pressure. Established players must innovate to differentiate their offerings, while generics threaten to erode profit margins in mature markets.

Market Segmentation

Loading chart…

Age-related Macular Degeneration segmentation by Type is categorized into Dry AMD and Wet AMD. Dry AMD, accounting for ~85–90% of cases, is characterized by the gradual accumulation of drusen and retinal pigment changes. It dominates the market due to its high prevalence and reliance on supportive therapies like nutritional supplements and low-vision aids. Wet AMD, though representing ~10–15% of cases, drives significant market growth due to its acute nature and demand for advanced treatments such as anti-VEGF injections. The cost and complexity of managing Wet AMD create a distinct revenue segment, with a higher dependency on pharmaceutical innovation and frequent medical interventions. This duality in market taxonomy ensures that therapeutic pipelines and diagnostic tools are tailored differently for each type, influencing the overall Age-related Macular Degeneration market size.

In Application, the Age-related Macular Degeneration market is segmented into Diagnosis, Treatment, and Prevention. Diagnosis includes imaging technologies like optical coherence tomography (OCT) and fundus photography, which are critical for early detection and monitoring disease progression. Treatment encompasses pharmacological interventions (e.g., anti-VEGF drugs, corticosteroids) and surgical options, forming the largest revenue segment due to chronic care requirements. Prevention focuses on lifestyle modifications, supplements (e.g., AREDS2 formula), and public health initiatives, though its market share remains smaller. The application-driven market taxonomy highlights evolving trends, such as the rise of telemedicine in diagnosis and the shift toward personalized treatment regimens. These segments collectively define the Age-related Macular Degeneration market dynamics, with treatment applications accounting for the most significant growth trajectory.

Age-related Macular Degeneration Segmentation Breakdown7 items

Type

Wet AMD

Dry AMD

Application

Drugstore

Hospital

Others

Regional Insights

Loading chart…

North America dominates the Age-related Macular Degeneration market growth with a 35% share, driven by advanced diagnostic infrastructure, high adoption of anti-VEGF therapies, and robust R&D investments. Europe follows at 25%, supported by favorable reimbursement policies and aging demographics. The Asia Pacific region, the fastest-growing market, is projected to expand at a CAGR of 8.5% through 2030, fueled by rising geriatric populations, improving healthcare access, and increasing disease awareness. Latin America and the Middle East & Africa collectively account for 15%, with growth hindered by fragmented healthcare systems but showing potential due to rising affluence and policy reforms.

Key Drivers by Region5 items

North America: Ecosystem maturity in ophthalmic care, high patient compliance, and aggressive pharmaceutical innovation.

Europe: Policy frameworks like the EU's Horizon Europe funding and cross-border collaboration in clinical trials.

Asia Pacific: Urbanization, telemedicine adoption, and partnerships between global biotechs and local stakeholders.

Latin America: Public-private initiatives to enhance diagnostic infrastructure and affordability of orphan drugs.

Middle East & Africa: Demographic transitions, growing insurance penetration, and government focus on non-communicable disease management.

The regional forecast underscores Asia Pacific’s potential to disrupt the market balance by 2030, while North America and Europe remain pivotal for therapeutic innovation. Strategic investments in early detection programs and pipeline therapies will determine the next phase of global market expansion.

Competitive Landscape

The Age-related Macular Degeneration competitive landscape is moderately consolidated, with global pharmaceutical firms dominating alongside niche biotech players. Key players leverage product innovation, regulatory approvals, and pricing strategies to differentiate in a high-growth, compliance-driven market. Global firms such as F. Hoffmann-La Roche and Novartis maintain strong positions through established anti-VEGF therapies, while regional companies like Avalanche focus on localized distribution and cost-competitive offerings. Competitive dynamics are shaped by rapid R&D cycles, with a focus on next-generation therapies such as gene and cell-based treatments. Pricing pressures from payor negotiations and biosimilar entry present a secondary challenge, though differentiation through clinical trial outcomes and patient adherence programs remains central.

Strategic priorities include M&A for pipeline expansion, partnerships for manufacturing scale, and geographic diversification to offset mature market saturation. Companies differentiate through proprietary technologies (e.g., Regeneron’s Eylea platform) or cost advantages via local manufacturing (e.g., Bausch+Lomb). A key challenge is managing supply chain risks for complex biologics, compounded by stringent regulatory requirements. Smaller firms like Iconic Therapeutics pursue niche applications in rare AMD subtypes to avoid direct competition. Localization of clinical trials and tailored reimbursement models further distinguish players in fragmented markets.

Bayer HealthCare: Innovation pipeline for gene therapy candidates.

F. Hoffmann-La Roche: Strategic partnerships for global distribution networks.

Novartis: Product launches targeting wet AMD with sustained-release formulations.

Regeneron Pharmaceuticals: Vertical integration of manufacturing for cost control.

Alcon: OEM tie-ups to expand ophthalmic device portfolio.

Avalanche: Regional expansion in emerging markets via licensing agreements.

Key Age-related Macular Degeneration Companies12 items

Bayer HealthCare

F. Hoffmann-La Roche

Novartis

Regeneron Pharmaceuticals

Alcon

Allergan

Avalanche

Bausch+Lomb

Gilead Sciences

Iconic Therapeutics

Neurotech Pharmaceuticals

Ohr Pharmaceutical

Market Ecosystem

The Age-related Macular Degeneration ecosystem spans upstream technology and raw material suppliers, midstream therapeutic developers and manufacturers, and downstream healthcare providers and patients. Value is generated through innovation in drug and device development, clinical validation, and efficient distribution of treatments, with revenue captured by stakeholders across research, production, and delivery phases.

Raw material suppliers — Provide active pharmaceutical ingredients and biologics for AMD therapies

Biopharmaceutical developers — Conduct R&D and clinical trials for novel anti-VEGF drugs and gene therapies

Contract manufacturers — Produce injectables, implants, and diagnostic tools under OEM agreements

Ophthalmic healthcare providers — Diagnose AMD and administer treatments via retina specialty clinics

Health insurers/payers — Cover treatment costs through Medicare, private insurance, and pharmacy benefit managers

Regulatory authorities — Oversee FDA/EU approval processes and post-market pharmacovigilance requirements

Data analytics firms — Support real-world evidence generation and patient outcome tracking for treatment optimization

Control points reside in regulatory approval pathways and reimbursement decisions, which determine market access for new therapies. Dependency risks include raw material availability, clinical trial enrollment challenges, and adherence to evolving diagnostic standards. Partnerships between developers and payers shape coverage policies, while interoperability requirements for digital diagnostic tools create technical integration bottlenecks.

Recent Industry Insights

The Age-related Macular Degeneration industry trends over the past 18 months reflect a dynamic landscape driven by innovation and strategic collaborations. Partnerships between biotech firms and AI-driven diagnostics companies, such as Regeneron’s alliance with Google Health to enhance early detection algorithms, underscore a shift toward _data-centric precision medicine_. Mergers and acquisitions, including Allergan’s acquisition of a gene therapy startup, have accelerated access to novel treatments like CRISPR-based solutions. Product launches, such as _sustained-release anti-VEGF implants_ by companies like Roche, highlight advancements in patient convenience. Regulatory bodies, notably the FDA, have prioritized fast-track approvals for therapies targeting geographic atrophy, while the EMA has expanded real-world evidence requirements. Consumer demand for at-home monitoring devices, such as smart contact lenses, aligns with the growing emphasis on remote care. Funding rounds for startups in the gene therapy and AI diagnostics space—surpassing $500M collectively—signal investor confidence in long-term market growth.

Analyst Overview

The Age-related Macular Degeneration (AMD) market outlook remains robust, driven by an aging global population and rising demand for innovative therapies. Market attractiveness is bolstered by unmet therapeutic needs, particularly in advanced AMD stages, and strong investment in R&D. Competitive intensity is high, with established biopharma giants and emerging biotechs vying for market share through pipeline advancements in gene therapy, anti-VEGF alternatives, and regenerative medicine.

The long-term outlook is optimistic, with market expansion projected through 2030, supported by advancements in precision diagnostics and personalized treatment paradigms. However, innovation faces hurdles such as high clinical trial costs and regulatory scrutiny. Demand currently outpaces supply for cutting-edge therapies, creating pricing pressures and access disparities. Key risk factors include reimbursement uncertainties, patent expirations of blockbuster drugs, and the potential for treatment resistance. Strategic partnerships and digital health integration will be critical to sustaining growth while addressing these challenges.

11 items

1. Executive Summary

2. Age-related Macular Degeneration Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Age-related Macular Degeneration Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Age-related Macular Degeneration Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. Wet AMD

6.1.2. Dry AMD

6.2. Global Age-related Macular Degeneration Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. Drugstore

6.2.2. Hospital

6.2.3. Others

6.3. Global Age-related Macular Degeneration Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Age-related Macular Degeneration Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Age-related Macular Degeneration Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Age-related Macular Degeneration Market Competition by Key Manufacturers

8.1. Global Age-related Macular Degeneration Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Age-related Macular Degeneration: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Bayer HealthCare

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. F. Hoffmann-La Roche

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Novartis

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Regeneron Pharmaceuticals

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Alcon

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Allergan

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Avalanche

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Bausch+Lomb

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Gilead Sciences

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Iconic Therapeutics

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Neurotech Pharmaceuticals

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Ohr Pharmaceutical

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Age-related Macular Degeneration Market

Figure 4: Global Age-related Macular Degeneration Market: Drivers

Figure 5: Global Age-related Macular Degeneration Market: Challenges

Figure 6: Global Age-related Macular Degeneration Market: Trends

Figure 7: Global Age-related Macular Degeneration Market: Opportunity

Figure 8: Global Age-related Macular Degeneration Market: Restraint

Figure 9: Global Age-related Macular Degeneration Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Age-related Macular Degeneration Market Value (USD Million) By Region

Figure 15: Global Age-related Macular Degeneration Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Age-related Macular Degeneration Market Value (USD Million) By Region

Figure 23: Global Age-related Macular Degeneration Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

77 items

Table 1: Market Segmentation Analysis

Table 2: Global Age-related Macular Degeneration Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Age-related Macular Degeneration Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Age-related Macular Degeneration Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Age-related Macular Degeneration Market Value (USD Million) By Region

Table 10: Global Age-related Macular Degeneration Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Age-related Macular Degeneration Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Age-related Macular Degeneration Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Age-related Macular Degeneration Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Bayer HealthCare Basic Information And Sales Area

Table 31: Bayer HealthCare. Products Portfolio

Table 32: F. Hoffmann-La Roche Basic Information And Sales Area

Table 33: F. Hoffmann-La Roche. Products Portfolio

Table 34: Novartis Basic Information And Sales Area

Table 35: Novartis. Products Portfolio

Table 36: Regeneron Pharmaceuticals Basic Information And Sales Area

Table 37: Regeneron Pharmaceuticals. Products Portfolio

Table 38: Alcon Basic Information And Sales Area

Table 39: Alcon. Products Portfolio

Table 40: Allergan Basic Information And Sales Area

Table 41: Allergan. Products Portfolio

Table 42: Avalanche Basic Information And Sales Area

Table 43: Avalanche. Products Portfolio

Table 44: Bausch+Lomb Basic Information And Sales Area

Table 45: Bausch+Lomb. Products Portfolio

Table 46: Gilead Sciences Basic Information And Sales Area

Table 47: Gilead Sciences. Products Portfolio

Table 48: Iconic Therapeutics Basic Information And Sales Area

Table 49: Iconic Therapeutics. Products Portfolio

Table 50: Neurotech Pharmaceuticals Basic Information And Sales Area

Table 51: Neurotech Pharmaceuticals. Products Portfolio

Table 52: Ohr Pharmaceutical Basic Information And Sales Area

Table 53: Ohr Pharmaceutical. Products Portfolio

Table 54: Global Market Value (USD Million) (2025-2032) By Type

Table 55: Global Market Share (%) By Type (2032)

Table 56: Global Market Value (USD Million) (2025-2032) By Application

Table 57: Global Market Share (%) By Application (2032)

Table 58: Global Age-related Macular Degeneration Market Value (USD Million) By Region

Table 59: Global Age-related Macular Degeneration Market Share (%) By Region (2025-2032)

Table 60: North America Market Value (USD Million) (2025-2032) By Country

Table 61: North America Market Value (USD Million) (2025-2032) By Type

Table 62: North America Market Value (USD Million) (2025-2032) By Application

Table 63: Europe Market Value (USD Million) (2025-2032) By Country

Table 64: Europe Market Value (USD Million) (2025-2032) By Type

Table 65: Europe Market Value (USD Million) (2025-2032) By Application

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 67: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 69: South America Market Value (USD Million) (2025-2032) By Country

Table 70: South America Market Value (USD Million) (2025-2032) By Type

Table 71: South America Market Value (USD Million) (2025-2032) By Application

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 73: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 75: Research Programs/Design For This Report

Table 76: Key Data Information From Secondary Sources

Table 77: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Age-related Macular Degeneration Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	7.95 billion
Revenue forecast in 2033	12.29 billion
Growth rate	CAGR of 5.6% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bayer HealthCare; F. Hoffmann-La Roche; Novartis; Regeneron Pharmaceuticals; Alcon; Allergan; Avalanche; Bausch+Lomb; Gilead Sciences; Iconic Therapeutics; Neurotech Pharmaceuticals; Ohr Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Age-related Macular Degeneration Segmentation Breakdown7 items

Type

Wet AMD

Dry AMD

Application

Drugstore

Hospital

Others

Regional Insights

Loading chart…

Key Drivers by Region5 items

North America: Ecosystem maturity in ophthalmic care, high patient compliance, and aggressive pharmaceutical innovation.

Europe: Policy frameworks like the EU's Horizon Europe funding and cross-border collaboration in clinical trials.

Asia Pacific: Urbanization, telemedicine adoption, and partnerships between global biotechs and local stakeholders.

Latin America: Public-private initiatives to enhance diagnostic infrastructure and affordability of orphan drugs.

Middle East & Africa: Demographic transitions, growing insurance penetration, and government focus on non-communicable disease management.

Competitive Landscape

Bayer HealthCare: Innovation pipeline for gene therapy candidates.

F. Hoffmann-La Roche: Strategic partnerships for global distribution networks.

Novartis: Product launches targeting wet AMD with sustained-release formulations.

Regeneron Pharmaceuticals: Vertical integration of manufacturing for cost control.

Alcon: OEM tie-ups to expand ophthalmic device portfolio.

Avalanche: Regional expansion in emerging markets via licensing agreements.

Key Age-related Macular Degeneration Companies12 items

Bayer HealthCare

F. Hoffmann-La Roche

Novartis

Regeneron Pharmaceuticals

Alcon

Allergan

Avalanche

Bausch+Lomb

Gilead Sciences

Iconic Therapeutics

Neurotech Pharmaceuticals

Ohr Pharmaceutical

Market Ecosystem

Raw material suppliers — Provide active pharmaceutical ingredients and biologics for AMD therapies

Biopharmaceutical developers — Conduct R&D and clinical trials for novel anti-VEGF drugs and gene therapies

Contract manufacturers — Produce injectables, implants, and diagnostic tools under OEM agreements

Ophthalmic healthcare providers — Diagnose AMD and administer treatments via retina specialty clinics

Health insurers/payers — Cover treatment costs through Medicare, private insurance, and pharmacy benefit managers

Regulatory authorities — Oversee FDA/EU approval processes and post-market pharmacovigilance requirements

Data analytics firms — Support real-world evidence generation and patient outcome tracking for treatment optimization

Recent Industry Insights

Analyst Overview

Table of Contents